What is the proper technique for administering intravenous terlipressin as a continuous infusion in an adult patient?

How to Administer Terlipressin as Continuous Infusion

Terlipressin should be administered as a continuous intravenous infusion starting at 2-4 mg/24 hours through a peripheral IV line, which is more effective and safer than bolus dosing, with fewer adverse events and lower total drug requirements.

Pre-Administration Assessment

Before initiating continuous terlipressin infusion, you must:

• Check oxygen saturation (SpO2) - Do not start if SpO2 <90% 1
• Assess for ACLF Grade 3 - These patients are at higher risk for respiratory failure 2, 1
• Rule out contraindications: active hypoxia, ongoing coronary/peripheral/mesenteric ischemia 2, 1
• Evaluate volume status - Avoid fluid overload before starting 2

Dosing Protocol for Continuous Infusion

Initial Dosing

• Start with 1 mg IV bolus, followed immediately by 4 mg continuous infusion over 24 hours 3, 4
• Alternative starting dose: 2 mg/24 hours can be used, particularly in HRS-AKI 5

Dose Titration

• If serum creatinine does not decrease by ≥25-30% after 48 hours, increase dose progressively 6, 5
• Maximum dose: 12 mg/24 hours 5
• Adjust based on clinical response and tolerance

Duration

• Continue until serum creatinine ≤1.5 mg/dL for 24 hours (two consecutive values at least 2 hours apart) 1
• Maximum duration: 14 days 2, 1
• Discontinue if creatinine remains at or above baseline after 4 days at maximum tolerated dose 7

Administration Technique

Route: Peripheral IV line is sufficient - central line NOT required 2

Preparation: Reconstitute lyophilized powder per manufacturer instructions 1

Infusion: Administer as continuous IV infusion over 24 hours using infusion pump

Line management: Flush IV line after administration 1

Concurrent Albumin Administration

• Day 1: 1 g/kg body weight 7, 5
• Subsequent days: 20-50 g/day 2, 7
• Critical caveat: Assess volume status carefully - excessive albumin increases respiratory failure risk 2
• Consider stopping albumin after 1-2 days if adequate volume expansion achieved 2

Monitoring Requirements

Continuous Monitoring

• Pulse oximetry throughout treatment per FDA label 1
• In practice outside the US, vital signs including SpO2 every 2-4 hours is acceptable 2

Clinical Assessments

• Respiratory status: Watch for dyspnea, hypoxia, respiratory failure 2, 1
• Ischemic symptoms: Abdominal pain, chest pain, peripheral ischemia 2, 7
• Volume status: Signs of fluid overload 2

Laboratory Monitoring

• Serum creatinine: Daily, or every 48 hours for dose adjustment 6, 5
• Electrolytes: Monitor for hyponatremia 2

Advantages of Continuous Infusion Over Bolus

The evidence strongly favors continuous infusion 2:

• Lower total daily dose required: 4 mg/day infusion vs 8 mg/day bolus 4, 6
• Fewer adverse events: 35-36% vs 56-62% with bolus 4, 5
• Better hemodynamic response: 85% vs 58% achieved >10% HVPG reduction at 24 hours 2, 4
• Lower rebleeding rates in variceal hemorrhage: 2% vs 15% 2
• Sustained splanchnic vasoconstriction with more stable drug levels 3, 5

Safety Considerations and Contraindications

Absolute Contraindications

• SpO2 <90% or worsening respiratory symptoms 1
• Active coronary, peripheral, or mesenteric ischemia 1

High-Risk Populations (Use with Extreme Caution)

• ACLF Grade 3: Increased respiratory failure risk 2, 1
• Serum creatinine >5 mg/dL: Unlikely to benefit 2, 1
• MELD ≥35: Risks may outweigh benefits 2

Common Adverse Events (Occur in >10%)

• Abdominal pain, nausea, diarrhea 2, 1
• Respiratory failure (14% in trials) 2
• Dyspnea 1

Management of Adverse Events

• If SpO2 drops below 90%: Discontinue immediately 1
• If ischemic symptoms develop: Reduce dose or discontinue 7
• If respiratory failure occurs: Stop terlipressin, manage volume status aggressively 2

Clinical Context and Pitfalls

Important caveat: While the FDA-approved regimen uses intermittent bolus dosing (0.85-1.7 mg every 6 hours) 1, the most recent 2024 AGA guidelines explicitly state that continuous infusion is supported by emerging data showing superior outcomes 2. Multiple RCTs from 2016-2025 consistently demonstrate that continuous infusion at 4 mg/24 hours is equally or more effective than higher-dose bolus regimens while causing significantly fewer adverse events 8, 4, 6, 5.

Common pitfall: Over-administration of albumin increases respiratory failure risk, particularly in patients with pre-existing volume overload 2. Reassess volume status daily and consider stopping albumin after initial resuscitation.

Setting of care: Continuous infusion does NOT require ICU admission - can be administered on regular medical floors with appropriate monitoring 2.